Your daily news brief — read it or listen to it in 5 minutes

Daily news brief — 28 March 2026

10 stories · 8 sources · 5 minute read

01world

Israel Expands Invasion of Southern Lebanon as UNICEF Warns Attacks Have Killed 121 Children

Israel is expanding its ground invasion into southern Lebanon, aiming to establish a buffer zone. UNICEF reports that Israeli attacks have killed 121 children and displaced over 370,000 people in the region.

Why it matters

The escalating conflict raises serious humanitarian concerns and could further destabilize an already volatile region.

Listen to this story

Sources

  • Democracy Now
02world

Russian Oil Exports Fall Dramatically After Ukraine Attacks Baltic Sea Terminals

Ukrainian drones struck Russian ports and refineries in the Baltic Sea region, halting roughly 40% of Russia's oil exports. The attack marks the largest supply disruption to Russian energy infrastructure since the war began, with damage visible from Finland.

Why it matters

Russia relies heavily on oil revenues to fund its war effort. A 40% export disruption could meaningfully strain its economy and military capacity.

Listen to this story

Sources

  • Democracy Now
03marketsCovered by 2 outlets

Investors Warned Against Panic Selling in War-Driven Correction

Strategists urge investors to hold diversified portfolios amid war-driven market declines, warning that exiting to bonds risks missing recoveries. The S&P 500 has rebounded from every major crisis, rewarding patience over reaction.

Why it matters

Reactive selling often locks in losses. History suggests disciplined, long-term investors consistently fare better through geopolitical volatility.

Listen to this story

Sources

  • Associated Press
  • Associated Press

“Why it matters” for the rest of today's stories is available in the Fivly app.

04business

Paramount-Warner Bros. Merger Expected to Trigger Thousands of Job Cuts

Paramount and Warner Bros. are moving toward a merger following a competitive bidding process. The consolidation is widely expected to result in thousands of job losses across both companies as the combined entity seeks efficiencies.

Listen to this story

Sources

  • Bloomberg Television
05tech

SoftBank Secures $40 Billion Loan for OpenAI Investments

SoftBank has secured a $40 billion bridge loan, backed by lenders including JPMorgan and Goldman Sachs, to fund investments in OpenAI and broader corporate needs. The deal underscores the enormous capital demands shaping the AI industry.

Listen to this story

Sources

  • Reuters
06ai

Luma AI Uni-1 vs Google: A New AI Breakthrough

Luma AI's Uni-1 model outperforms Google's Nano Banana in reasoning-based imaging, style, and editing tasks. It uses autoregressive generation and operates at 10–30% lower costs than its competitor.

Listen to this story

Sources

  • Precedence Research
07business

Regional Banking Sector Faces Major Consolidation Wave

The regional banking sector is experiencing a significant consolidation wave, with multiple institutions positioned as both potential acquirers and acquisition targets. Citi is among those exploring deal opportunities amid the shifting landscape.

Listen to this story

Sources

  • Bloomberg Television
08tech

Apple to Open Siri to Rival AI Assistants in iOS 27

Apple plans to open Siri to third-party AI services such as Google Gemini and Anthropic Claude in iOS 27, according to Bloomberg. The move would turn Siri into a gateway platform rather than a standalone assistant, with deeper cross-app functionality.

Listen to this story

Sources

  • Bloomberg
09ai

GPT-5.4 and the Logic of Native Computer Interaction

OpenAI has deployed GPT-5.4 with native computer-use capabilities, allowing AI agents to manage applications, files, and workflows directly. The update delivers 33% fewer errors compared to GPT-5.2.

Listen to this story

Sources

  • devFlokers
10health

FDA Approves Awiqli® (insulin icodec-abae), First Once-Weekly Basal Insulin for Type 2 Diabetes

The FDA has approved Awiqli, Novo Nordisk's once-weekly basal insulin, marking the first of its kind for adults with type 2 diabetes. The approval follows Phase 3 ONWARDS trials involving 2,680 adults, supporting its use alongside diet and exercise for glycemic control.

Listen to this story

Sources

  • Endocrine News